Skip to main content
. 2016 Sep;101(9):1074–1081. doi: 10.3324/haematol.2016.143073

Figure 2.

Figure 2.

Overall and relapse-free survival rates in AML cases with and without DMRGM. (A) Overall survival rate for all cases. (B) Relapse-free survival rate for all cases. (C) Overall survival rate in FLT3-ITD-negative cases aged ≤ 70 years with intermediate cytogenetic prognosis. (D) Relapse-free survival rate in FLT3-ITD-negative cases aged ≤ 70 years with intermediate cytogenetic prognosis. HR: Hazard ratio.